Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SI-B001 in recurrent or metastatic head and neck squamous cell carcinoma
CTR20211979Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Nov 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab in head and neck squamous cell carcinoma (HNSCC), sponsored by Biokin Pharmaceutical. Started Nov 2021; status: active.
02
Drugs
izalontamab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20211979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211979.